TRAX (First Tracks Biotherapeutics) Earnings Yield %: % (As of Jul. 13, 2026)


TRAX First Tracks Biotherapeutics Inc TRAX
12 GF Score
Price $36.24
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Earnings Yield %?

First Tracks Biotherapeutics TRAX +11.85% 12 Earnings Yield % is % as of Jul. 13, 2026. GuruFocus rates TRAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

As of today (2026-07-13), the stock price of First Tracks Biotherapeutics is $36.24. First Tracks Biotherapeutics does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024. Therefore, GuruFocus does not calculate First Tracks Biotherapeutics's earnings yield at this moment.

The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. First Tracks Biotherapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

First Tracks Biotherapeutics  (NAS:TRAX) Earnings Yield % Explanation

If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.

Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.

Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %.

Be Aware

Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.

First Tracks Biotherapeutics Earnings Yield % Related Terms

TRAX
12GF Score
First Tracks Biotherapeutics Inc TRAX
Earnings Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Earnings Yield % Calculation

Earnings yield is the reciprocal of the P/E Ratio.

First Tracks Biotherapeutics's Earnings Yield for today is calculated as

Earnings Yield=Earnings per Share (Diluted) (TTM)/Share Price
=/36.24
= %

It can also be calculated from the numbers for the whole company:

Earnings Yield=Net Income /Market Cap

The earnings in the calculation is the Trailing Twelve Months earnings.

Frequently Asked Questions Learn more about Earnings Yield % →
What does a Earnings Yield % of % mean?
First Tracks Biotherapeutics (TRAX) has a Earnings Yield % of % as of Jul. 13, 2026. Earnings Yield equals per-share earnings divided by share price. It is the inverse of the price-earnings ratio. View historical data on First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Earnings Yield % too high?
First Tracks Biotherapeutics' current Earnings Yield % is %. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Earnings Yield % compare to ALT and RGNX?
First Tracks Biotherapeutics' Earnings Yield % of % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield % for a Biotechnology company?
A good Earnings Yield % depends on the Biotechnology industry context. However, Earnings Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield % mean?
A high Earnings Yield % can signal that a stock is expensive relative to its fundamentals. Earnings Yield equals per-share earnings divided by share price. It is the inverse of the price-earnings ratio. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Earnings Yield % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current Earnings Yield % of %. The current Earnings Yield % is %. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield % calculated?
Earnings Yield % is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current Earnings Yield % is % as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges B43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for TRAX

Earnings Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.24
Price